Arch Therapeutics Announces $2.85 Million Private Placement
January 31, 2014 06:00 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jan 31, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...
Arch Therapeutics Presents 2014 Milestones During Live Webcast
January 22, 2014 11:00 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jan 22, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...
Arch Therapeutics to Present Status Update and Milestone Overview at Noble Financial Capital Markets' Tenth Annual Equity Conference
January 14, 2014 09:00 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jan 14, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...
Arch Therapeutics to Webcast Live From the Biotech Showcase Investor Conference
January 08, 2014 09:00 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jan 8, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of AC5™, a novel product aimed at...
Arch Therapeutics Co-Founder Dr. Ellis-Behnke to Speak at Nanomanufacturing Summit 2013 in Philadelphia, October 15, 2013
October 10, 2013 09:00 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Oct 10, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), is pleased to announce that co-founding and inventing scientist, Dr. Rutledge...
Arch Therapeutics Announces Approval of $1 Million Massachusetts Life Sciences Center Accelerator Loan
October 07, 2013 09:00 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Oct 7, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of AC5™, a novel product aimed at...
Arch Therapeutics Announces Participation at the 2013 Boulder Peptide Symposium in Colorado September 25-27
September 20, 2013 09:00 ET
|
Arch Therapeutics, Inc.
CAMBRIDGE, MA--(Marketwired - Sep 20, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), today announced it will be featured as a presenting company at the Boulder Peptide...
Arch Therapeutics Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
September 03, 2013 09:00 ET
|
Arch Therapeutics, Inc.
CAMBRIDGE, MA--(Marketwired - Sep 3, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), today announced it will be featured as a presenting company at the 15th Annual Rodman...
Arch Therapeutics Announces Plans for Upcoming Activities
August 06, 2013 15:05 ET
|
Arch Therapeutics, Inc.
CAMBRIDGE, MA--(Marketwired - Aug 6, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5™, a novel product aimed at...
Arch Therapeutics Reports on Current Activities
July 30, 2013 09:00 ET
|
Arch Therapeutics, Inc.
CAMBRIDGE, MA--(Marketwired - Jul 30, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5™, a novel product aimed at...